Cypress Capital’s ResMed RMD Stock Holding History

Cypress Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-219	Closed	-$41.9K	–	292
2024 Q2	$41.9K	Buy	+219	New	+$44.4K	0.01%	124

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Cypress Capital's RMD Position: Q3 2024 in Review

Cypress Capital sold out of ResMed (RMD) in Q3 2024, closing a stake of 219 shares — an estimated $41.9K sold.

Cypress Capital first reported a position in RMD in Q2 2024 and held it in 1 quarter. The position peaked at $41.9K in Q2 2024. 801 funds tracked by Wall St. Rank hold RMD as of Q3 2024.

Cypress Capital reported no remaining ResMed position as of Q3 2024 after selling out during the quarter.
Cypress Capital sold 219 ResMed shares in Q3 2024, an estimated $41.9K.
Cypress Capital first reported a position in ResMed in Q2 2024 and held it in 1 quarter.
Cypress Capital's ResMed position peaked at $41.9K in Q2 2024.
801 funds tracked by Wall St. Rank held ResMed as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.